Integrated analysis of microRNA-target interactions with clinical outcomes for cancers

BackgroundClinical statement alone is not enough to predict the progression of disease. Instead, the gene expression profiles have been widely used to forecast clinical outcomes. Many genes related to survival have been identified, and recently miRNA expression signatures predicting patient survival have been also investigated for several cancers. However, miRNAs and their target genes associated with clinical outcomes have remained largely unexplored.MethodsHere, we demonstrate a survival analysis based on the regulatory relationships of miRNAs and their target genes. The patient survivals for the two major cancers, ovarian cancer and glioblastoma multiforme (GBM), are investigated through the integrated analysis of miRNA-mRNA interaction pairs.ResultsWe found that there is a larger survival difference between two patient groups with an inversely correlated expression profile of miRNA and mRNA. It supports the idea that signatures of miRNAs and their targets related to cancer progression can be detected via this approach.ConclusionsThis integrated analysis can help to discover coordinated expression signatures of miRNAs and their target mRNAs that can be employed for therapeutics in human cancers.

[1]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[2]  Shinji Tanaka,et al.  miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. , 2010, Carcinogenesis.

[3]  Xin Zhou,et al.  Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. , 2011, Oncology reports.

[4]  Israel Steinfeld,et al.  miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors , 2011, PloS one.

[5]  G. Chiappetta,et al.  FEZ1/LZTS1 protein expression in ovarian cancer , 2010, Journal of cellular physiology.

[6]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[7]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[8]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[9]  A. Fire,et al.  Patterns of known and novel small RNAs in human cervical cancer. , 2007, Cancer research.

[10]  P. Rolland,et al.  Loss of IFNγ Receptor Is an Independent Prognostic Factor in Ovarian Cancer , 2007, Clinical Cancer Research.

[11]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[12]  Stefano Volinia,et al.  Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer , 2013, Proceedings of the National Academy of Sciences.

[13]  Yunqing Li,et al.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. , 2009, Cancer research.

[14]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[15]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[16]  Michael Sabel,et al.  Genomic and Expression Profiling of Glioblastoma Stem Cell–Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival , 2009, Clinical Cancer Research.

[17]  Ming Liu,et al.  Role of MicroRNA-26b in Glioma Development and Its Mediated Regulation on EphA2 , 2011, PloS one.

[18]  Shucheng Ma,et al.  Increased Expression of microRNA-17 Predicts Poor Prognosis in Human Glioma , 2012, Journal of biomedicine & biotechnology.

[19]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[20]  Shiguang Zhao,et al.  MiR-106a is an independent prognostic marker in patients with glioblastoma. , 2013, Neuro-oncology.

[21]  Sandra L. Rodriguez-Zas,et al.  Transcription Factor-MicroRNA-Target Gene Networks Associated with Ovarian Cancer Survival and Recurrence , 2013, PloS one.

[22]  Hao Jiang,et al.  Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. , 2009, International journal of oncology.

[23]  C. Sander,et al.  Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma , 2012, PloS one.

[24]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Ju Han Kim,et al.  Synergistic effect of different levels of genomic data for cancer clinical outcome prediction , 2012, J. Biomed. Informatics.

[26]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[27]  Junxing Chen,et al.  Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer. , 2012, Oncology letters.

[28]  C. Hedvat,et al.  Tumor promoting properties of the ETS protein MEF in ovarian cancer , 2007, Oncogene.

[29]  T. Dalmay,et al.  MicroRNAs and the hallmarks of cancer , 2006, Oncogene.

[30]  Nectarios Koziris,et al.  TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support , 2011, Nucleic Acids Res..

[31]  M. Lubin,et al.  Selective Killing of Tumors Deficient in Methylthioadenosine Phosphorylase: A Novel Strategy , 2009, PloS one.

[32]  J. Chi,et al.  Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma , 2008, Journal of cellular and molecular medicine.

[33]  F. Slack,et al.  microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. , 2009, Cancer research.

[34]  Joanna H Shih,et al.  Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Gao,et al.  Increased expression of miR-148b in ovarian carcinoma and its clinical significance. , 2012, Molecular medicine reports.

[36]  Tim Beißbarth,et al.  Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer , 2011, BMC Bioinformatics.

[37]  H. Ohgaki,et al.  Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population‐based study , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.

[38]  S. Tribius,et al.  ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. , 2001, International journal of radiation oncology, biology, physics.

[39]  P. Rolland,et al.  Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Shamit Soneji,et al.  Microrna expression distinguishes between germinal center B cell‐like and activated B cell‐like subtypes of diffuse large B cell lymphoma , 2007, International journal of cancer.

[41]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[42]  P. Cairns,et al.  LOT1 (PLAGL1/ZAC1), the Candidate Tumor Suppressor Gene at Chromosome 6q24–25, Is Epigenetically Regulated in Cancer* , 2003, The Journal of Biological Chemistry.